Fabrício Alves Barbosa da Silva

Dr. Fabrício Alves Barbosa da Silva

Scientific Computing Programme, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003
Verified
Conference Paper
Closed access
WCW. Cirne
W. Cirne
DPD. Paranhos
D. Paranhos
LCL. Costa
L. Costa
ESE. Santos-Neto
E. Santos-Neto
FBF. Brasileiro
F. Brasileiro
CSC. Silveira
C. Silveira
We here discuss how to run Bag-of-Tasks applications on computational grids. Bag-of-Tasks applications (those parallel applications whose tasks are independent) are both relevant and amendable for execution on grids. However, few users currently execute their Bag-of-Tasks applications on grids. We investigate the reason for this state of affairs and introduce MyGrid, a system designed to overcome the identified difficulties. MyGrid provides a simple, complete and secure way for a user to run Bag-of-Tasks applications on all resources she has access to. Besides putting together a complete solution useful for real users, MyGrid embeds two important research contributions to grid computing. First, we introduce some simple working environment abstractions that hide machine configuration heterogeneity from the user. Second, we introduce work queue with replication (WQR), a scheduling heuristics that attains good performance without relying on information about the grid or the application, although consuming a few more cycles. Note that not depending on information makes WQR much easier to deploy in practice

8 May 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
FBFlávia Campos Barcelos
Flávia Campos Barcelos
GMGuacira Corrêa de Matos
Guacira Corrêa de Matos
MSMARIO JORGE SOBREIRA DA SILVA
MARIO JORGE SOBREIRA DA SILVA
FSFabrício Alves Barbosa da Silva
Fabrício Alves Barbosa da Silva
ELElisangela Costa Lima
Elisangela Costa Lima
Spontaneous reporting systems may generate a large volume of information in real world conditions with a relatively low cost. Disproportionality measures are useful to indicate and quantify unexpected safety issues associated with a given drug-event pair (signals of disproportionality), based upon differences compared to the background reporting frequency. This cross-sectional study (2008 to 2013) aimed to analyse the feasibility of detecting such signals in the Brazilian Pharmacovigilance Database comprising suspected adverse drug reactions related to the use of doxorubicin, cyclophosphamide, carboplatin, trastuzumab, docetaxel, and paclitaxel for breast cancer chemotherapy. We first accessed overall database features (patient information and suspected adverse drug reactions) and further conducted a disproportionality analysis based on Reporting Odds Ratios with a confidence interval of 95% in order to identify possible signals of disproportionate reporting, only among serious suspected adverse drug reactions. Of all data reports of adverse reactions (n = 2603), 83% were classified as serious, with the highest prevalence with docetaxel (78.1%). The final analysis was performed using 1,309 reports with 3,139 drug-reaction pairs. The following signals of disproportionate reporting, some rare or not mentioned on labels, were observed: tachypnea with docetaxel; bronchospasm, syncope, cyanosis, and anaphylactic reaction with paclitaxel; and anaphylactic shock with trastuzumab. Structured management of spontaneous adverse drug reaction reporting is essential for monitoring the safe use of drugs and detecting early safety signals. Disproportionality signal analysis represents a viable and applicable strategy for oncology signal screening in the Brazilian Pharmacovigilance Database.

21 October 2019 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
ACAlessandra J. Conforte
Alessandra J. Conforte
Jack TuszynskiJack Tuszynski
Jack Tuszynski
FSFabrício Alves Barbosa da Silva
Fabrício Alves Barbosa da Silva
Nicolas CarelsNicolas Carels
Nicolas Carels
Traditional approaches to cancer therapy seek common molecular targets in tumors from different patients. However, molecular profiles differ between patients, and most tumors exhibit inherent heterogeneity. Hence, imprecise targeting commonly results in side effects, reduced efficacy, and drug resistance. By contrast, personalized medicine aims to establish a molecular diagnosis specific to each patient, which is currently feasible due to the progress achieved with high-throughput technologies. In this report, we explored data from human RNA-seq and protein–protein interaction (PPI) networks using bioinformatics to investigate the relationship between tumor entropy and aggressiveness. To compare PPI subnetworks of different sizes, we calculated the Shannon entropy associated with vertex connections of differentially expressed genes comparing tumor samples with their paired control tissues. We found that the inhibition of up-regulated connectivity hubs led to a higher reduction of subnetwork entropy compared to that obtained with the inhibition of targets selected at random. Furthermore, these hubs were described to be participating in tumor processes. We also found a significant negative correlation between subnetwork entropies of tumors and the respective 5-year survival rates of the corresponding cancer types. This correlation was also observed considering patients with lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) based on the clinical data from The Cancer Genome Atlas database (TCGA). Thus, network entropy increases in parallel with tumor aggressiveness but does not correlate with PPI subnetwork size. This correlation is consistent with previous reports and allowed us to assess the number of hubs to be inhibited for therapy to be effective, in the context of precision medicine, by reference to the 100% patient survival rate 5 years after diagnosis. Large standard deviations of subnetwork entropies and variations in target numbers per patient among tumor types characterize tumor heterogeneity.

27 June 2017 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
MCMarcelo Rodrigo de Castro
Marcelo Rodrigo de Castro
CTCatherine dos Santos Tostes
Catherine dos Santos Tostes
ADAlberto Davila
Alberto Davila
HSHermes Senger
Hermes Senger
FSFabrício Alves Barbosa da Silva
Fabrício Alves Barbosa da Silva
The demand for processing ever increasing amounts of genomic data has raised new challenges for the implementation of highly scalable and efficient computational systems. In this paper we propose SparkBLAST, a parallelization of a sequence alignment application (BLAST) that employs cloud computing for the provisioning of computational resources and Apache Spark as the coordination framework. As a proof of concept, some radionuclide-resistant bacterial genomes were selected for similarity analysis. Experiments in Google and Microsoft Azure clouds demonstrated that SparkBLAST outperforms an equivalent system implemented on Hadoop in terms of speedup and execution times. The superior performance of SparkBLAST is mainly due to the in-memory operations available through the Spark framework, consequently reducing the number of local I/O operations required for distributed BLAST processing.

1 February 2009 in Parallel Computing
Verified
Journal Article
Closed access
FSFabrício Alves Barbosa da Silva
Fabrício Alves Barbosa da Silva
HSHermes Senger
Hermes Senger

6 August 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JVJean Mendes de Lucena Vieira
Jean Mendes de Lucena Vieira
GMGuacira Corrêa de Matos
Guacira Corrêa de Matos
FSFabrício Alves Barbosa da Silva
Fabrício Alves Barbosa da Silva
LBLouise E. Bracken
Louise E. Bracken
MPMatthew Peak
Matthew Peak
ELElisangela Costa Lima
Elisangela Costa Lima
Children are more exposed to inappropriate medicine use and its consequent harms. Spontaneous reporting of suspected Serious Adverse Drug Reactions (SADR) increases knowledge and prevention of pharmacotherapy risk. Disproportionality measures are useful to quantify unexpected safety issues associated with a given drug-event pair (signals of disproportionality). This cross-sectional study aimed to assess SADR reporting and safety signals for Brazilian children from 0-12 years old, notified between January 2008 and December 2013 from the Brazilian Surveillance Agency (Notivisa). Information from serious reports (gender and age of the patient, event description, suspected drug) was included. Disproportionality analysis based on Reporting Odds Ratios with a confidence interval of 95% was conducted to identify possible signals of disproportionate reporting (SDR). Almost 30% of 1,977 suspected SADR was related to babies (0-1-year-old). 69% of reports happened with intravenous dosage forms, and 35% of suspected SADR involved off label use according to age. Laronidase, miglustat, imipenem/cilastatin, and clofarabine were involved in six or more suspected deaths among 75 deaths reported. There were 107 SDRs, of which 16 events (15%) were not described in the product labels. There was a relatively higher number of SADRs in Brazilian children compared with studies from other countries. SDRs found, (especially drug-event pairs ‘imipenen/cilastatin–pneumonia’ and ‘laronidase–respiratory insufficiency’) should be investigated more. The reports of SADR with IV dosage forms and OL drug use suggest the need for drug research and the use of better dosage forms for children in Brazil.